Pharmacodynamics of orally administered sustained-release hydromorphone in humans

Anesthesiology

Volumn 94, Issue 1, 2001, Pages 63-73

  Angst, Martin S ^a   Drover, David R ^a   Lötsch, Jörn ^a,b   Ramaswamy, Bhamini ^a   Naidu, Sujata ^a   Wada, D Russell ^c   Stanski, Donald R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c PHARSIGHT CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE; HYDROMORPHONE SR; PLACEBO;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION;

EID: 0035166114     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200101000-00014     Document Type: Article

References (41)

1. Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA
2. New clinical-practice guidelines for the management of pain in patients with cancer
3. Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study
4. Opioid rotation for cancer pain: Rationale and clinical aspects
5. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain
6. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain
7. How often is medication taken as prescribed? A novel assessment technique
8. Overview of patient compliance with medication dosing: A literature review
9. Effects of controlled-released morphine on quality of life for cancer pain
10. Controlled release metoprolol formulations: A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease
11. The nifedipine gastrointestinal therapeutic system (GITS): Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties
12. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder
13. Lumbar epidural morphine in humans and supraspinal analgesia to experimental heat pain
14. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models
15. Controlled-release morphine tablets in patients with chronic cancer pain: A narrative review of controlled clinical trials
16. Hydromorphone analgesia after intravenous bolus administration
17. Morphine and ibuprofen compared using the cold pressor test
18. Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers
19. Influence of polarity on dose-response relationships of intrathecal opioids in rats
20. The influence of drug polarity on the absorption of opioid drugs into CSF and subsequent cephalad migration following lumbar epidural administration: Application to morphine and pethidine
21. Experimental pain in healthy human subjects: Gender differences in nociception and in response to ibuprofen
22. The hypoalgesic effect of imipramine in different human experimental pain models
23. An analgesic comparison of floctafenine (Idarac) and dihydrocodeine in post-operative pain
24. Analgesic efficacy and potency of two oral controlled-release morphine preparations
25. Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopaedic surgery: A randomized, double-blind, placebo and standard active drug comparison
26. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone
27. Pharmacokinetic properties of tramadol sustained release capsules. 1st Communication: Iinvestigation of dose linearity
28. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain
29. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain
30. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain
31. Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer
32. Patient-controlled analgesic administration: A comparison of steady- state morphine infusions with bolus doses
33. Quality of life on angina therapy: A randomised controlled trial of transdermal glyceryl trinitrate against placebo
34. Influence of drug formulation on drug concentration-effect relationships
35. Relief of pain by infusion of morphine after operation: Does tolerance develop?
36. The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy
37. Influence of food on the bioavailability of metoprolol from an OROS system; a study in healthy volunteers
38. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy
39. Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: A short report